Telix sells targeted cancer imaging and treatments, but growing competition and changing payment rules could squeeze what it earns from its leading prostate product. The long-term promise in next‑generation “see and treat” cancer care is still there, yet building and running a complex manufacturing network could be the make‑or‑break factor.Read more
Telix shifts from a one-product story into a wider platform, using its growing manufacturing and distribution network to bring more imaging and treatment tools to hospitals around the world. The big question is whether that expansion turns into steadier profits, or whether heavy spending, tougher competition, and regulatory scrutiny slow the payoff.Read more
Catalysts About Telix Pharmaceuticals Telix Pharmaceuticals develops and commercializes radiopharmaceutical imaging and therapeutic products for oncology and other serious diseases. What are the underlying business or industry changes driving this perspective?Read more
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with advanced metastatic kidney cancer; TLX400, a bladder fibroblast activation protein for treating various tumors; TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma; TLX300 for treating soft tissue sarcoma; and TLX090, a bone-seeking agent for bone metastases and pain palliation. In addition, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis; AlFluor, a novel PET radiochemistry solution; TLX250-Px, a PET diagnostic imaging agent; and TLX101-Px, a radiolabeled amino acid PET agent. It operates in Australia, Belgium, Canada, the United Kingdom, the United States, and internationally. The company has strategic collaboration with University Hospital Essen. The company was founded in 2015 and is headquartered in North Melbourne, Australia.
